CeNeRx BioPharma

CeNeRx completes $4.85 million financing round

Monday, December 12, 2011

CeNeRx BioPharma has completed a $4.85 million financing. Existing investors Perseus Soros Biopharmaceutical Fund, L Capital Partners, Pappas Ventures and Omega Funds all participated in the financing. CeNeRx plans to use the proceeds to complete its ongoing phase II trial of the improved formulation of its novel antidepressant TriRima as monotherapy in treatment resistant depression, as well as to support advancement of its pipeline for a variety of CNS disorders.

[Read More]